Wei Li, Ph.D.
Picture
Wei Li, Ph.D.
Professor and Knights Templar Eye Foundation Presidential Chair in Ophthalmology
Phone
Phone
Positions
- Professor and Knights Templar Eye Foundation Presidential Chair in Ophthalmology
-
Ophthalmology
Baylor College of Medicine
Houston, Texas United States
Addresses
- Neurosensory Center (Office)
-
6565 Fannin St
NC416
Houston, TX 77030
United States
Education
- PhD from University of Nebraska Medical Center
- 12/1991 - Omaha, Nebraska United States
- MS from Zhejiang University College of Medicine
- 06/1986 - Hangzhou, China
- BSc from Zhangjiang University College of Pharmacy
- 06/1983 - Hangzhou, China
Professional Statement
Our research goals are to advance our knowledge of disease mechanisms and develop novel therapies to relive patient suffering. Our laboratory has been studying ligand-receptor interactions for cell-cell communication that has been traditionally studied on a case-by-case basis with inherent technical challenges. We created the only paradigm of “ligandomics” to globally map cell-wide ligands. Comparative ligandomics for diseased versus healthy cells is capable of systematically identifying disease-selective ligands. Our team further developed “function-first” and “therapy-first” ligandomics approaches to independently characterize functional activity, disease selectivity, pathogenic role and therapeutic potential of identified ligands. These innovative methods have led to the discovery of secretogranin III (Scg3) as a novel disease-selective angiogenic factor. Scg3 is a neuron-derived angiogenic factor that functions as a disease-restricted neurovascular regulator. We generated Scg3-neutralizing antibodies and confirmed their high efficacy to alleviate multiple neovascular diseases, including diabetic retinopathy, retinopathy of prematurity and choroidal neovascularization, with minimal side effects on healthy vasculature. In contrast, all currently approved anti-angiogenic drugs target both diseased and healthy vessels with side effects. Our findings highlighted ligandomics as a powerful technology for disease mechanism research and drug target discovery.Ongoing projects in my laboratory include: i) Developing anti-Scg3 antibodies toward clinical translation for next-generation disease-targeting anti-angiogenic therapy; ii) characterizing other disease-selective ligands for their pathogenic role and therapeutic potentials; iii) mapping other neurovascular crosstalk and inter-system cell-cell communications using our innovative ligandomics technology in different disease conditions; and iv) developing next-generation ligandomics technology that will expand the application of the technology to any cells, tissues and diseases to unravel disease mechanisms and efficiently develop novel ligand-guided disease-targeting therapies.
Selected Publications
- Tang, F., LeBlanc, M.E., Wang, W., Liang, D., Chen, P., Chou, T., Tian, H., Li, W. "Anti-Secretogranin III Therapy of Oxygen-Induced Retinopathy with Optimal Safety.." Angiogenesis. 2019 Aug;22(3):369-382. Pubmed PMID: 30644010
- Rong, X., Tian, H., Yang, L., Li, W. "Function-first ligandomics for ocular vascular research and drug target discovery.." Exp. Eye Res.. 2019 May;182:57-64. Pubmed PMID: 30904565
- LeBlanc, M.E., Wang, W., Ji, Y., Tian, H., Liu, D., Zhang, X., Li, W. "Secretogranin III as a novel target for the therapy of choroidal neovascularization.." Exp. Eye Res.. 2019 Apr;181:120-126. Pubmed PMID: 30633921
- Li, W., Pang, I.H., Pacheco, M.T.F., Tian, H. "Ligandomics: A paradigm shift in biological drug discovery.." Drug. Discov. Today.. 2018 Mar;23(3):636-643. Pubmed PMID: 29326083
- LeBlanc, M.E., Wang, W., Caberoy, N.B., Chen, X., Guo, F., Alvarado, G., Shen, C., Wang, F., Wang, H., Chen, R., Liu, Z., Webster, K., Li, W. "Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease.." PloS One. 2017 Nov;20(4):479-492. Pubmed PMID: 28447229
- LeBlanc, M.E., Wang, W., Chen, X., Caberoy, N.B., Guo, F., Chen, X., Ji, Y., Tian, H., Wang, H., Chen, R., Li W. "Secretogranin III as a disease-associated ligand for anti-angiogenic therapy of diabetic retinopathy.." J. Exp. Med.. 2017 Apr;214(4):1029-1047. Pubmed PMID: 28330905
- Li, W., Webster, K.A., LeBlanc, M.E., Tian, H. "Secretogranin III: A diabetic retinopathy-selective angiogenic factor.." Cell. Mol. Life. Sci.. 2017 Feb;75(4):635-647. Pubmed PMID: 28856381
- Caberoy, N.B. Zhou, Y., and Li, W. "Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis.." EMBO J.. 2010 Dec;29(23):3898-3910. Pubmed PMID: 20978472
- Li, W. "ORF phage display to identify cellular proteins with different functions.." Methods. 2012 Sep;58(1):2-9. Pubmed PMID: 22836128
- Caberoy, N.B., Zhou, Y., Jiang, X., Alvarado, G., and Li, W. "Efficient identification of tubby-binding proteins by an improved system of T7 phage display.." J. Mol Recognit.. 2010 Feb;23(1):74-83. Pubmed PMID: 19718693
- Li, W and Caberoy, N.B. "New perspective for phage display as an efficient and versatile technology of functional proteomics.." Appl. Microbiol. Biotechnol.. 2010 Jan;85(4):909-919. Pubmed PMID: 19885657
Funding
- Next-generation ligandomics technology to globally map cellular ligands of the retina - #1R43EY031643-01A1
- $226,255.00 (09/01/2020 - 08/31/2021) Grant funding from NIH
- The goal of this project is to develop next-generation technology of ligandomics to systematically map disease-selective ligands.
- Anti-angiogenic gene therapy of ocular vascular diseases - #R43EY031238-01
- $225,000.00 (07/01/2020 - 06/30/2021) Gift funding from NIH
- The goal of this grant is to develop a novel anti-angiogenic gene therapy to treat neovascular age-related macular degeneration (AMD) in animal models.
- A selective angiogenesis blocker to treat or prevent retinopathy of prematurity - #R24EY028764
- $9,126,317.00 (02/01/2019 - 12/31/2023) Grant funding from NIH/NEI
- The goal of this project is to develop a novel anti-angiogenic therapy to treat retinopathy of prematurity, an eye disease in preterm infants.
- A diabetic retinopathy-associated vascular permeability factor - #R01EY027749
- $1,918,749.00 (06/01/2018 - 05/31/2023) Grant funding from NIH/NEI
- The goal of this project is to investigate the mechanisms and disease selectivity of Scg3 as a diabetic retinopathy-selective vascular leakage factor.
- A novel disease-selective therapy for diabetic retinopathy - #1-18-IBS-172
- $345,000.00 (01/01/2018 - 12/31/2020) Grant funding from American Diabetes Association
- The goal of this project is to investigate Scg3 as a disease selective vascular leakage factor for the therapy of diabetic retinopathy.
Intellectual Property
- Open-reading frame (ORF) phage display
- Method Patent #8,754,013 (Approved)
- Co Inventors: Xiaoyu Jiang, Nora Blanca Caberoy
- Quantitative ligandomics for systematic identification of therapeutic ligands
- Method Patent #10,106,787 (Approved)
- Quantitative ligandomics for systematic identification of therapeutic ligands
- Method Patent #15/860170 (Pending)
- Divisional patent application split from US Patent #10,106,787
- Anti-secretogranin III (Scg3) antibodies and uses thereof
- Method Patent #PCT/US17/60189 (Pending)
- Co Inventors: Michelle E. LeBlanc, Weiwen Wang, Philip J. Rosenfeld
Log In to edit your profile